neurology Archives – European Brain Council (EBC)

Funding the Future of Brain Research in Europe: Towards a European Brain Health Partnership | Congress of the European Academy of Neurology

Dominika Suchonova — Sat, 21 Jun 2025 11:30:00 +0000

Neurological and mental disorders are a leading cause of mortality and disability in Europe and globally, putting a great burden on people living with brain disorders, their professional and informal carers, as well as healthcare systems and national economies. To take on this grand challenge, a coordinated, sustainable, and holistic research and innovation initiative, the European Partnership for Brain Health, is envisaged and will begin in January 2026 as a major joint effort of the European Commission, Member States and Associated Countries in collaboration with international partners. By capitalising on existing initiatives, synergies will be formed and links with all relevant stakeholders in the brain health sector and beyond will be strengthened to increase and align efforts and funding. This session will explore the goals and reasons behind the planned Partnership – and why it’s incredibly timely – as well as the expected impact (in terms of research investment, interventions and care), the Strategic Research and Innovation Agenda and how the EP BrainHealth will pave the way towards an overall (brain) healthier society.

This TV Studio Session “Funding the Future of Brain Research in Europe: Towards a European Brain Health Partnership” will take place on 21 June 2025 at 11:30-12:00 (Helsinki time) at the 11th Congress of the European Academy of Neurology in Helsinki (Finland).

Meet the speakers!

Dr Catherine Marquer

International coordinator for Neurosciences, French National Research Agency

Frédéric Destrebecq

Executive Director, European Brain Council

Dr Ulrike Bußhoff

Coordinator, Coordination and Support Action BrainHealth

Learn more about the EBC activities at the Congress!

The post Funding the Future of Brain Research in Europe: Towards a European Brain Health Partnership | Congress of the European Academy of Neurology appeared first on European Brain Council (EBC).

10th Congress of the European Academy of Neurology

Dominika Suchonova — Sat, 29 Jun 2024 00:00:00 +0000

The 10th annual congress of the European Academy of Neurology will take place in Helsinki (Finland) and online on 29 June – 2 July, 2024.

The Overarching Theme for EAN 2024 is ‘Neuromodulation: advances and opportunities in neurological diseases’, with numerous sessions planned around this important and engaging topic.

As usual, the congress programme will be bursting with Symposia, Workshops, Teaching Sessions, and much more, including some exciting Named Lectures from eminent invited speakers.

EBC looks forward to being part of the exhibition area and holding the following sessions:

Multiple Sclerosis (MS) and Amyotrophic Lateral Sclerosis (ALS): advancing clinical decision making through wearables, poster presentation
Assessing the Digital Care Pathways Unmet Needs for Rare Brain Diseases. The Case of Phenylketonuria, poster presentation, 2 July, 12:52
Toward a European Brain Health Plan, EAN TV Studio Session, 29 June 2024, 11:30-12:30
Digital Care Pathways for Rare Brain Diseases. The Case of Phenylketonuria, Scientific Theatre, 30 June 2024, 12:15-12:45
EBC: Towards the European Partnership on Brain Health, Scientific Theatre, 30 June 2024, 15:45-16:15
Uniting Multiple Sclerosis and Amyotrophic Lateral Sclerosis Research Innovations through Collaborative Endeavours, Scientific Theatre, 1 July 2024, 14:05-14:35

For more information about EAN 2024 – including programme – please explore the congress website!

Find out more!

The post 10th Congress of the European Academy of Neurology appeared first on European Brain Council (EBC).

3rd International Conference on Neurological Disorders and Neurorestoration

Hugo Hermantin — Thu, 09 May 2024 00:00:00 +0000

The International Conference on Neurological Disorders and Neurorestoration will be held from 9^th– 12^th May 2023 in Brijuni National Park, Croatia.

This unique international meeting will cover a wide range of areas connected to neurology, neuroscience and neurorestoration, such as neuroinflammation, neurodegeneration, ischemic diseases, paroxysmal and extrapyramidal diseases. The School of Medicine of the University of Zagreb, supported by all clinics for neurology of the Zagreb Clinical and Hospital Centers, is the main organizer of the conference.

The conference will be organized in conjunction with the 10^th Academy Meeting of National Brain Councils that will be held from 8^th– 9^th May.

More information about the event will be available soon.

PDF Presentation

The post 3rd International Conference on Neurological Disorders and Neurorestoration appeared first on European Brain Council (EBC).

EAN Congress: Rethinking the management of brain disorders: Alzheimer’s disease & migraine

Dominika Suchonova — Sat, 01 Jul 2023 11:00:00 +0000

The European Brain Council (EBC) is pleased to hold a Scientific Theatre on “Rethinking the management of brain disorders: Alzheimer’s disease & migraine” on 1 July 20223 at 11:00 – 11:30 during the 9th Annual Congress of the European Academy of Neurology in Budapest (Hungary).

Despite improvements and innovation in recent years, people living with brain conditions, neurological and mental alike, face variations in access to optimal treatment and care. There is a lot about brain disorders that is not fully understood and the high-quality care and support needed by people living with these conditions is often unavailable.

The aim of the RETHINKING Projects is to develop policy priorities around challenges in brain disorders and present a consensus on what needs to be achieved to resolve the most pressing challenges in brain conditions, today and in the future. There is a clear need to rethink the management of the brain disorders and redesign the care pathways to ensure optimal treatment and care for all people living with brain disorders in Europe.

The speakers of the session will present how to rethink the way we manage Alzheimer’s disease and migraine in terms of their prevention, detection and diagnosis.

Find out more about the session

Speakers

Dr. Kristian Steen Frederiksen, Co-chair, EAN Scientific Panel Dementia and Cognitive Disorders, European Academy of Neurology

Dr. Michela Tinelli, Assistant Professorial Research Fellow and NIHR SSCR Leadership Fellow, London School of Economics, London School of Economics

The post EAN Congress: Rethinking the management of brain disorders: Alzheimer’s disease & migraine appeared first on European Brain Council (EBC).

European Brain Health Summit 2023

Stephanie Kramer — Tue, 09 May 2023 17:00:00 +0000

European Brain Health Summit 2023

Tuesday May 9, 2023, 17.00 – 20.00 CEST

The European Academy of Neurology (EAN) held two first Brain Health events in 2022: The Brain Health Summit in May in Vienna and the Brain Health Event at the European Parliament in December. Both events highlighted the importance of advocacy for neurology, alongside cooperation with national societies, international authorities, organisations, and other stakeholders.

This year’s Summit will focus on European Brain Health Summit: Precision neurology and prevention of neurological diseases.

Visit the website for more information:

Programme

The post European Brain Health Summit 2023 appeared first on European Brain Council (EBC).

15th Congress of the European Paediatric Neurology Society (EPNS)

Dominika Suchonova — Tue, 20 Jun 2023 00:00:00 +0000

The 15^th Congress of the European Paediatric Neurology Society (EPNS) will take place on 20-24 June 2023 in the Congress Center Prague.

The main highlight of the congress is “From genome and connectome to cure”. EPNS invites you to see how the latest trends in understanding pathophysiology of neurological diseases are being implemented in clinical practice. The field has traditionally focused on precise diagnostics; however, curative treatments were unavailable for a long time. Today, this trend is changing rapidly and novel therapeutic options in our field have brought hope to many families of children even with the most severe neurological conditions.

EBC looks forward to being part of the exhibition area where you will have a chance to learn more about our ongoing projects, upcoming events and activities.

Visit the official website and find out more!

For privacy reasons YouTube needs your permission to be loaded. For more details, please see our Privacy Policy.

The post 15th Congress of the European Paediatric Neurology Society (EPNS) appeared first on European Brain Council (EBC).

EBC at EAN Congress 2022

Stephanie Kramer — Sat, 25 Jun 2022 00:00:00 +0000

EBC was pleased to be part of this year’s Congress of the European Academy of Neurology, which took place in person on 25-28 June 2022 in Vienna, Austria. Alongside an Exhibition Stand in the EAN Neurohood, EBC had a Special Session take place on 28 June at 13:00-14:30 (Room Berlin), celebrating 20 Years of Advocacy for the Brain. The session featured the following presentations:

Introduction & Moderation by Prof. Wolfgang Oertel, President, European Brain Council
History of the European Brain Council by Prof. Jes Olesen, Founding President, European Brain Council
Involving patients and the Value of Treatment by Joke Jaarsma, Treasurer, European Brain Council and President, European Federation of Neurological Associations
Advocating for the brain: the European Brain Research Area by Frédéric Destrebecq, Executive Director, European Brain Council

Additionally, EBC projects such as the European Brain Research Area (EBRA) and the Value of Treatment were showcased at the congress in the Scientific Theatre and through ePosters.

Scientific Theatres:
– EBC Value of Treatment (VOT) Study – Bridging gaps and achieving seamless, coordinated care, a study on rare neurological and neurometabolic disorders by the European Brain Council – 25 June 2022, 14:00 – 14:30 (Theatre 09)
– EBC Value of Treatment (VOT) Study – A Comparison of Optimal Management vs Current Management of Chronic Pain– 27 June 2022, 10:00-10:30 (Theatre 25)
– European Brain Research Area (EBRA): Outcome and results of the Horizon 2020 project – 28 June 2022, 10:30-11:00 (Theatre 37)

ePosters:
– EBC Value of Treatment (VOT) Study – A Comparison of Optimal Management vs Current Management of Chronic Pain – 26 June 2022, 12:30 to 13:15 (Screen B7)
– EBC Value of Treatment (VOT) Study – Assessing the Value of Specialist Centres for the Diagnosis and Management of the Ataxias in Europe – 26 June 2022, 12.30-13.15 (Screen A9)

The post EBC at EAN Congress 2022 appeared first on European Brain Council (EBC).

OneNeurology Global Advocacy Workshop

Stephanie Kramer — Tue, 29 Jun 2021 08:30:00 +0000

EBC recently joined the OneNeurology Partnership. The focus of this Partnership in 2021 will be in influencing the development of the World Health Organisation’s new Global Action Plan on epilepsy and other neurological disorders [GAP].

The GAP represents a unique opportunity to build an integrated response to neurology across the life course and within healthcare systems – to improve lives of people living with neurological disorders worldwide. However, to be successful, we need to mobilise the community to ensure that the plan serves the needs of all those living with neurological disorders across the globe.

We are now searching for effective advocates at national and regional levels to get involved, in working with us to develop our response to the first draft of the GAP, and to advocate at all levels for a plan that addresses the real burden of neurological disorders.

If you are interested in learning more and getting actively involved, the OneNeurology Partnership will host, on June 29^th 2021, a virtual Global Advocacy Workshop where we will:

Present the first draft of the GAP to advocates worldwide
Present the views of the OneNeurology Partnership on the first draft of the GAP
Bring together neurology advocates from across the world (regional and national), to gather their perspectives on the GAP – based on their region/disease area/stakeholder group.
Empower global advocates with the information, tools and resources needed to ensure a coordinated response to the GAP consultation via submissions, regional hearings and outreach to national policy makers.

The event is open to individual health care professionals, researchers, people living with neurological disorders, their carers or anyone else who is interested in engaging in neurology advocacy. Advocates may also come from the organisations who represent these various stakeholder groups.

To cater for all timezones, there will be two sessions during the day.

Session 1: 8.30-11am CET or Session 2: 4.30-7pm CET

Or find out more at: www.oneneurology.net

The post OneNeurology Global Advocacy Workshop appeared first on European Brain Council (EBC).

Event Report: “Patient Engagement in EU-Funded Brain Research Projects”

Stephanie Kramer — Fri, 26 Mar 2021 10:37:36 +0000

On 16 March 2021, on the occasion of Brain Awareness Week 2021, the European Brain Council, in partnership with the European Federation of Neurological Associations & GAMIAN-Europe, held an event on Patient Engagement in EU-Funded Brain Research Projects.

The event aimed to shed light on the current state of patient engagement in EU-funded brain research projects, exploring how patients have been involved to date, their experiences in this involvement, the challenges continued to be faced, examples of patient-involved projects and initiatives and looking at what can be done to improve engagement.

EBC, EFNA and GAMIAN-Europe were pleased to welcome over 100 participants. The event was opened by Prof Monica Di Luca, President of EBC, who – speaking as a basic scientist – highlighted the fundamental importance of patient involvement in research in order to gain knowledge from the lived experience of patients to boost research findings to work towards understanding and discovering proper treatment and cures for brain disorders. Patient engagement is a central force in many EBC activities, particularly in the European Brain Research Area (EBRA) project and in the EBC Policy Roadmap ‘Brain Health in Europe: Fostering Innovation, Improving Outcomes’ released on the day.

From here the programme shifted to setting the scene, with Irene Norstedt, Director, People Directorate, DG Research and Innovation, European Commission; Erik Van der Eycken, EU Research Project Officer, GAMIAN-Europe presenting their views on the challenges of engaging patients in research; and Joke Jaarsma, President of European Federation of Neurological Associations (EFNA) President & Treasurer of EBC.

One of the key issues to put on the table is the understanding of the role and expectation [for patients in research]. It is very clear that it has to be a real participation and not a token participation. This is something that we’ve had for many years in the European Commission with projects often having a requirement to have patient participation in research that we are funding and what we really need to highlight is the importance to make sure that patients and/or patient representatives are not put there as tokens but really are given an active role.

Irene Norstedt, Director, People Directorate, DG Research and Innovation, European Commission

Communication is a very important aspect and key challenge in patient involvement. Overcoming language barriers is not only understanding the various European languages but also the type of language that you have between the researchers and the patients/patient representatives. In my experience, in different projects we talk a very different language. This is not only between patients and researchers but also between patients and patient representatives, making sure we understand how to communicate their wishes, their requirements.

Erik Van der Eycken, EU Research Project Officer, GAMIAN-Europe

How to actually involve patients in the research process is still not fully defined. In spite of the fact that patient involvement has become a key element in patient-centred healthcare and it is clear that patient involvement such as working with the clinical research community as co-creators of clinical trials can help make research outcomes and end points more meaningful to both patients and caregivers. There is enough evidence by now that this can help make research more focused and acceptable, starting with asking the right research questions, creating appropriate clinical trials right through to regulatory HTA.

Joke Jaarsma, President, EFNA & Treasurer, EBC

After outlining the ongoing challenges, both from the funder perspective and the patients’ perspective, three invited speakers presented work within their organisations and/or projects, giving concrete examples of actively engaging patients: Pierre Meulien, Executive Director of the Innovative Medicines Initiative (IMI); Paola Zaratin, Project Coordinator of MULTI-ACT; and Patrik Vankrunkelsven, Director of the Belgian Centre for Evidence-based Medicine (CEBAM).

European initiatives such as the Innovative Medicines Initiative (IMI) have spearheaded the growth of involving patients in European research, encouraging patient involvement in their activities and project, and involving patients as speakers and panelists in their events and consultations. IMI, as a funding body, needs to continuously work to innovate and update their strategic thinking, which saw the launch of the IMI Pool of Patient Experts last year. This works to “put the patients at the same level as any scientific, clinical, ethical or economics expert and being able to use their own patient experience as a key asset in each stage of the research project life cycle” and gathers patients from all across the EU that can be called upon to help provide guidance within IMI activities and projects. There are currently 157 patients/carers from 26 EU countries registered – the pool is also open to family members and carers. 30% currently cover neuropsychiatric and neurodegenerative disorders.

H2020-funded projects such as MULTI-ACT were launched with the aim to increase the impact of health research on people with brain diseases and to create and implement a new model allowing for the effective cooperation of all relevant stakeholders. The MULTI-ACT White Paper for innovative routes for patient engagement is a high-level policy-oriented document addressing key actions to be taken in the short, medium and long term by policymakers and research & innovation funders to foster patient engagement in health R&I. It calls for policymakers to take action and implement innovative routes for patient engagement in R&I, leading to research outcomes that matter most to patients and society.

One of the main activities of the Belgian Centre for Evidence-based Medicine (CEBAM) is validating guidelines, which has seen a very fast-paced evolution of the importance of patient involvement. “Just 5 years ago we judged patient involvement as ‘not so important’, however, nowadays, it is really required to involve patients in the development of guidelines, otherwise we cannot validate it.” CEBAM is currently working on the development of a website on “Health and Science” for patients, trying to augment health literacy with the understandable and easy-to-digest presentation of thousands of health guidelines alongside fact-checking of [research-related] news.

The event then shifted back to the original panel of Irene Norstedt, Director, People Directorate, DG Research and Innovation, European Commission; Erik Van der Eycken, EU Research Project Officer, GAMIAN-Europe presenting their views on the challenges of engaging patients in research; Joke Jaarsma, President of European Federation of Neurological Associations (EFNA) President & Treasurer of EBC, also joined by Tomislav Sokol, Member of the European Parliament (HR, EPP). MEP Sokol spoke on the need for structured dialogue and engagement of patients at the EU-wide level, citing the challenges of healthcare being a Member State competence but also the small steps towards change gained by EU-wide programmes/initiatives such as the Cancer Plan and EU4Health. The panel went on to react to the concrete solutions presented by IMI, MULTI-ACT and CEBAM and answered questions from the audience.

The fact that obviously primary competence of organising health care systems and regulating patients’ rights is on the national level; but this was in many cases just used as an alibi for lacking common EU vision of what kind of healthcare provision we want. This is definitely changing and I think that on EU level we have some positive developments, obviously the COVID-19 pandemic has put healthcare, patient needs and patient engagement more to the centre of EU decision making.

We need more structured dialogue and engagement with patient organisations, not just at a formal level in conferences, events, etc. but to really engage them in real decision making in working groups, in creating white papers and at the very start of different legislative and policy initiatives.

Tomislav Sokol, Member of the European Parliament (EPP, HR)

Apart from engaging amongst themselves in the event chat and with speakers during the Q&A, audience members were also able to engage directly in the topic by filling out a pre-event survey, which gathered information about attendees. Around a third of the audience filled out the survey, and of the surveyed audience members, 21% were patients. When asked to rate the amount of involvement patients are given in EU research projects, the audience gave a score of 2.6/5; furthermore, when asked to rate the importance patients are given within research projects, the score was also low, 3.0/5. Additionally, and on a point touched by speakers, the audience was also asked whether they felt patients are given enough support and/or guidance to actively choose to become patient experts, and 79% answered no. In fact, much more work is yet to be done for patient engagement.

The audience was also asked to provide input on the same question posed to the speakers: what are the challenges of engaging patients in research?

These were some responses received:

“Researchers are afraid of losing focus if they involve patients.”

“Many patients (& carers!) already have a hard time because they are dealing with a serious disease. And they don’t get financially rewarded for investing their time and energy. In patient organizations, there already is a lot of extra work to do: bureaucracy & supporting others takes almost all our energy and time already. It’s difficult to find committed, long-term volunteers.”

“The Idea that it’s too hard to involve patients.”

“Connecting patients with researchers, providing patients with adequate information on their diagnosis, treatment possibilities, and clinical trials.”

“Time to generate a diverse and representative patient pool: Involving only 1 patient in a research project leads very easily to overfitting, especially as the patient involved is usually not a good representation of the whole population. It is important to meet with several patients, also the invisible majority, to build solutions that make sense for the targeted group. Experience on how to involve patients (how to maximize their value to the project): Researchers sometimes have a tendency to patronize patients, or to project their views on the patients’ views. Researchers could learn how to interact with patients (and every patient can bring something different to the table) to maximize the value each patient can bring to the project.”

“PPI groups are often not fully representative of the total patient population. They tend to be better informed and higher educated. How can we Ensure that the views of the PPI group truly represent the wider patient population?”

“There is often quite a big gap between the results from research and clear, concrete messages of how that research benefits patients. Researchers prefer to stay close to their research findings, that are limited to certain situations or conditions and don’t want to oversell their research. Patients on the other hand want clear and simple answers and solutions. In addition, researchers often want to understand how something works (i.e. the genetics of a disease) while patients want to know how they can get better. It is often difficult to explain why research is such a slow process, and that it can take many many years before fundamental research is translated into clinical care.”

“[Patients] not knowing about opportunities, what to expect, thinking that they need to have technical knowledge or be highly educated, sub-groups in particular not hearing about it or not feeling things apply to them or that they their views would be valued etc.”

“Patients should be introduced to PPI in a pragmatic, practice-oriented way; have access to support, should have ongoing feedback.”

“Do patients need to be involved in all types of research? Does all research need to be relevant for patients? A lot of research is done to gain knowledge on a topic that seems not relevant for patients now but which will benefit patients and society in the long term. We cannot only focus on short term goals in research projects. That’s not how science works. The biggest challenge is to define the research domains where patients can directly contribute and use their subjective experience. It makes no sense to involve patients in research in which they cannot use their experience. Their subjective experience is the most valuable expertise they have but patients do not have to become neuroscientists themselves.”

Lastly, together with our speakers, the question “how can patient involvement in research be improved?” was explored:

“Patients’ education and training so patients and researchers can understand each other, facilitate peer training (patients who have been involved in research training other patients who can be future research participants), make patient involvement in research more visible to the public, HTA bodies….”

“Generating patient pools and developing tools to generate fair involvement for all the parties.”

“Meaningful involvement of Patients in the research from the design of the research proposal, development, results through to the implementation and treated as full partners in research.”

“To have patients involved from the very beginning on a patient council where they are properly compensated as everyone else in the project. This would help to inform on the barriers and would encourage PwP to take part in the research project as it has been developed with an understanding of the lives experience. Also to include patients in what they want looked at not always what the pharmaceuticals want.”

“More financial support, especially for European disease-specific federations.”

“Creating patient councils to advise researchers on patient priorities, providing opportunities to bring patients and researchers together.”

“To the groundwork of meeting with patients, in their home setting, in their clinical setting, and learn to see the world through their lenses. – Accept that each patient is a human, with different interests, capacities, focuses, than the other patients/humans: learn how to maximize the value of each human to the research question.”

“Now, it is often researchers who involve PPI, but it can also be done the other way around, that PPI contact researchers if they see a problem that needs to be addressed.”

“Involving patient representatives already at the proposal writing stage, and have them as partners in consortia, is already a big step forward. The next step is to involve patients in formulating the research questions and to have a real dialogue between researchers and patients, at all stages of the research (i.e. citizen science).”

“By increasing awareness of researchers about PI and reaching out more actively to a more diverse group of patients.”

“Giving the sense of being and active actor, and giving the information to understand the data management principles and best practices.”

“By shared learning in groups consisting of both patients and researchers.”

“Patient involvement is a too broad and too general concept. Patient involvement can only be improved if both the patients and the researchers are aware of the value of involving patients. That’s why an effort should be put in explaining to basic scientists why they should involve patients in their research. Good arguments need to be provided but might be difficult to find for some areas in research. Only by seeing the added value/expertise/experience that patients bring, researchers will be convinced. For now, researchers involve patients because the commission or their institutions ask for it and their chances to be funded will increase. This is not a good motivation to include patients. In addition, researchers should become more aware of the importance and relevance of soft, “subjective”, phenomenological data instead of only focusing and trusting objective data (e.g., brain imaging) which are not reflecting the experience of the patients and are thus not relevant to patients. Researchers should be “obliged” to include such data in their research.”

“Make patients AND researchers aware of the advantages of patient involvement.”

The panel discussion was closed by moderator, Frédéric Destrebecq, Executive Director of the European Brain Council, echoing the importance many speakers placed on “driving a change” for patients and patient engagement in EU research.

Hilkka Kärkkäinen, President of GAMIAN-Europe, closed the event emphasising the importance of the discussion held on the day and the fact that it is clear that most patients and patient representatives still feel like not enough support is given to have their voices fully heard in research. “All stakeholders should know that patient involvement is meaningful and valuable and that patients are ready, willing and able to get involved. It is not acceptable to approach patients and/or patient organisations last minute looking for endorsement or help in disseminating research outcomes—they should be involved from the start!”

Hilkka highlighted the continued need for the establishment of patient expert pools, trust and relationship building amongst stakeholders and training of expert patients and researchers (much like EUPATI). She finished her address calling for EU policymakers to recognise the value of involving patients in research, including financial support for patient organisations to help foster grassroots patient engagement in research.

Thank you to all who attended and for your active engagement. The chat was very active during the event and we would like to highlight and share a few resources shared and discussed:

The post Event Report: “Patient Engagement in EU-Funded Brain Research Projects” appeared first on European Brain Council (EBC).

EBC at EAN Congress 2019

admin_ebc — Wed, 03 Jul 2019 12:21:03 +0000

EBC was present again this year at the Congress of the European Academy of Neurology, marking their 5th year of annual congresses. This year the congress was held in Oslo, Norway, and EBC was pleased to be able to participate in the Exhibition Hall as well as in the Scientific Theatre and EFNA-EAN Special Session.

The EBC Exhibition Stand was filled with materials this year – new and old – with a new EBC and EBRA brochure now available as well as the Value of Treatment, MULTI-ACT, MS Policy Narrative, Brain Mission and Election Manifesto documents readily available.

The Scientific Theatre provided a more relaxed area of presentation, and EBC was able to coordinate the presentation of both its current major projects, MULTI-ACT and EBRA.

As Project Coordinators, EBC presented EBRA, providing a general introduction of the project and the next steps to come to an audience of clinicians, industry and patients.

MULTI-ACT was presented by consortium member, Dr. Marcin Kautsch.

Lastly, EBC was also invited to speak at the EFNA-EAN Joint Symposium, “Norwegian Brain Strategy: a plan to strengthen brain health in Europe“. Prof. Hachinski gave the opening presentation on the Global Brain Alliance, with is working to increase the recognition of the growing burden of brain disorders worldwide, and EBC Executive Director, Frédéric Destrebecq, gave insight into the development of national brain plans as a growing necessity as tools for pushing the brain to the top of the EU agenda, and how the network of National Brain Councils can play a role in this.

The post EBC at EAN Congress 2019 appeared first on European Brain Council (EBC).